17,613 Shares in GSK plc (NYSE:GSK) Purchased by J2 Capital Management Inc

J2 Capital Management Inc purchased a new stake in GSK plc (NYSE:GSK) during the 4th quarter, HoldingsChannel reports. The fund purchased 17,613 shares of the pharmaceutical company’s stock, valued at approximately $596,000.

Other large investors have also recently modified their holdings of the company. FMR LLC increased its stake in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of GSK in the 2nd quarter worth about $52,487,000. Fisher Asset Management LLC increased its position in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in GSK by 33.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock worth $86,875,000 after buying an additional 569,614 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.0 %

Shares of GSK opened at $33.46 on Friday. The stock has a market capitalization of $69.34 billion, a P/E ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a fifty day simple moving average of $34.02 and a two-hundred day simple moving average of $37.98.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is currently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.